



OPEN

Author Correction: Isoliquiritigenin modulates miR-374a/PTEN/Akt axis to suppress breast cancer tumorigenesis and metastasis

Fu Peng, Hailin Tang, Peng Liu, Jiangan Shen, Xinyuan Guan , Xiaofang Xie, Jihai Gao, Liang Xiong, Lei Jia, Jianping Chen & Cheng Peng

Correction to: *Scientific Reports* <https://doi.org/10.1038/s41598-017-08422-y>, published online 21 August 2017

This article contains an error in Figure 5.

As a result of an error during figure assembly, images collected for the same sample were used to represent different conditions in Figure 5A, timepoint 0h. The corrected Figure 5 and its accompanying legend appear below.

Published online: 20 June 2023




Figure 5. Pretreatment of miR-374a in MDA-MB-231 attenuates the responses to ISL. **(A)** Representative images of wound healing assay in miR-NC and miR-374a mimic transfected groups after 24 h ISL treatment. **(B)** Chamber migration and invasion assay analysis of the effect of miR-374a transfection on breast cancer motile ability with ISL interference. **(C)** Percentages of closures of the wound in miR-374a-modulated MDA-MB-231 cells by 24 h exposure to ISL. **(D,E)** Percentages of the number of cells located on the lower side of chambers and Matrigel-coated chambers in the presence of ISL with miR-374a interference. Data represent the mean \pm s.d. * $P < 0.05$, ** $P < 0.01$.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023